Equity Overview
Price & Market Data
Price: $5.65
Daily Change: $0.00 / 0.00%
Range: $0 - $0
Market Cap: $182,339,632
Volume: 0
Performance Metrics
1 Week: -1.40%
1 Month: %
3 Months: 9.50%
6 Months: 32.94%
1 Year: -42.58%
YTD: 12.77%
Company Details
Employees: 110
Sector: Health technology
Industry: Medical specialties
Country: United States
Details
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics for improving outcomes for patients with difficult-to-treat liver and pancreatic cancers. It offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. The company also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and pancreatic cancer. It serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.